As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.
The melanocytes attacked by the autoimmune disease are present in the eyes and ears, not just the skin, so vitiligo can adversely affect vision and hearing.
Two specialists discuss prevalence, patient communication, and exciting new therapy.
Seemal Desai, MD, shares highlights from his session at Winter Clinical Hawaii.
Several dietary approaches have been proposed to play a role in the pathogenesis, management, and/or therapy of diseases such as vitiligo.
PDT has an advantage in that it can combine easily with other therapies, thereby increasing its effectiveness rates.
Clinicians should strive to address the unique medical and aesthetic challenges seen in vitiligo.
Latin America presents a patchwork of challenges and opportunities in vitiligo management according to a review published in the Journal of Dermatological Treatment.
Research has begun to explore natural compounds that address the oxidative stress, autoimmunity, and altered melanogenesis that drive vitiligo pathogenesis.
Following 2 phase 3 trials, the European Medicines Agency Committee for Medicinal Products for Human Use gives positive opinion on the use of ruxolitinib cream as a treatment for facial-involved non-segmental vitiligo.
By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.
The investigational oral JAK1 inhibitor showed promising results for vitiligo patients.
According to new research, vitamin D and serum brain-derived neurotrophic factors may exacerbate depression in some dermatologic patients.
Researchers said laser and intense pulse light-induced vitiligo lacks consensus in prevention and safety measures.
Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care.
Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.
Researchers have identified what may be the first report of vitiligo induced de novo by dupilumab therapy.
Researchers compared counts between patients with vitiligo and a control group of patients.
The pigment disorder is associated with several autoimmune and systemic comorbidities.
Hamzavi spoke at the 2023 Pigmentary Disorder Exchange Symposium in Chicago.
Pandya gives an in-depth overview of his vitiligo treatment pearls from the 2023 Pigmentary Disorders Exchange Symposium.
More research is needed to specify long-term efficacy of the treatment and its ideal dose.
Investigators compared data among patients with vitiligo and the general population.
Despite this, researchers found that Hsp70 plasma levels did not correlate with the extent of disease.
In recognition of World Vitiligo Day, the Dermatology Times team is spotlighting advances and educational opportunities for the condition.
The combination of therapies achieved significant efficacy, with researchers noting a higher cure rate than is evident in other therapies for the condition.
Trained immunity may act as an enhancer and continuous trigger in the disease’s pathogenesis.
The authorization comes just over 2 months after the drug’s approval in the European Union.
As we have surpassed the halfway mark of 2023, Dermatology Times is spotlighting vitiligo coverage and news from the first half of year.
Incyte representative Todd Edwards discusses how the awards help address challenges faced by patients with vitiligo.
A systematic review found that combination therapy proved more efficacious in treating patients with vitiligo as opposed to the excimer laser alone.
A pediatric patient with treatment-resistant vitiligo experienced improvements in depigmentation in as few as 9 treatments.
The multi-million-dollar study will identify signatures of at-risk patients that may predispose them to developing vitiligo.
Scientists say the new findings could lead to new drugs for vitiligo and other pigmentation diseases.
Both modalities achieved positive results and accurate ablation in cultured epithelial sheets transplantation for patients with vitiligo.
PRP is both safe and effective and may be used as a therapeutic option or alternative in conditions like vitiligo or in wound healing.
The VIOLIN study examined the burden of disease, prevalence, and treatment of vitiligo in patients in France.
Clinicians can use culturally competent care to ease patients’ concerns with identity and better understand the emotional toll of the condition.
Vitiligo and psychiatric disorders share a strong connection, with up to 90% of vitiligo patients having comorbid psychiatric conditions.
Investigators evaluated the most important markers associated with the pathogenesis of vitiligo, including serum inflammatory and oxidative stress markers.
A real-world retrospective analysis also found that among patients receiving treatment, most were unlikely to use more than 1 treatment or switch to an alternative treatment during the first year of diagnosis.
In a population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about the risks of mortality among these patients.
Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.
AbbVie announced the 24- and 52-week data at EADV 2023.
Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.
Investigators believe different circulating inflammatory phenotypes in patients with vitiligo may influence their responses to treatment with ruxolitinib cream.
Combined with routine treatments for vitiligo, certain CPMs proved efficacious in patients with vitiligo, with few adverse effects.
Incorporating vitamin D may mitigate adverse effects of corticosteroids, though more research is needed to discover the best methods for topical administration in vitiligo.
Susan C. Taylor, MD, FAAD, and George Han, MD, PhD, share insights on vitiligo awareness, demographics, treatment approaches, and the impact of the condition on patients’ quality of life.
Experts Heather Woolery-Lloyd, MD; Chesahna Kindred, MD, MBA, FAAD; Gary M. Owens, MD; and Renata Block, MMS, PA-C, discuss the evolving landscape of vitiligo, particularly from an economic lens.
Recently, a significant breakthrough was achieved when 42 international vitiligo experts and 4 patient representatives collaborated and developed a consensus management strategy for vitiligo.